Inventiva (NASDAQ:IVA) Trading Up 10.1% – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was up 10.1% on Thursday . The stock traded as high as $4.25 and last traded at $4.4490. Approximately 345,206 shares traded hands during trading, a decline of 19% from the average daily volume of 426,642 shares. The stock had previously closed at $4.04.

Wall Street Analyst Weigh In

IVA has been the subject of several recent research reports. Truist Financial initiated coverage on shares of Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target for the company. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Stock Performance

The business’s 50 day moving average is $5.32 and its two-hundred day moving average is $5.40.

Inventiva (NASDAQ:IVA) last announced its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. On average, analysts expect that Inventiva S.A. Sponsored ADR will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the period. Creative Planning acquired a new position in shares of Inventiva in the 2nd quarter valued at about $32,000. Commonwealth Equity Services LLC lifted its stake in shares of Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares during the period. Virtu Financial LLC acquired a new position in shares of Inventiva in the 4th quarter valued at about $60,000. Finally, XTX Topco Ltd acquired a new position in shares of Inventiva in the 4th quarter valued at about $84,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.